2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Hepatic Encephalopathy D006501 9 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Nervous System Diseases D009422 37 associated lipids
Brain Edema D001929 20 associated lipids
Starvation D013217 47 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Baldassarri S et al. The endocannabinoid 2-arachidonoylglycerol activates human platelets through non-CB1/CB2 receptors. 2008 J. Thromb. Haemost. pmid:18647220
Hoover HS et al. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. 2008 Bioorg. Med. Chem. Lett. pmid:18657971
Llorente R et al. Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: a possible role for the endocannabinoid system. 2008 Dev Neurobiol pmid:18666205
Ellgren M et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. 2008 Eur Neuropsychopharmacol pmid:18674887
Fowler CJ and Ghafouri N Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? 2008 Pharmacol. Res. pmid:18675915
Burston JJ et al. N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. 2008 J. Pharmacol. Exp. Ther. pmid:18682568
Nomura DK et al. Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. 2008 Bioorg. Med. Chem. Lett. pmid:18752948
Placzek EA et al. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. 2008 Neuropharmacology pmid:18760289
Avraham Y et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist, in various rat tissues during the evolution of experimental cholestatic liver disease. 2008 Jul-Aug Prostaglandins Leukot. Essent. Fatty Acids pmid:18771906
Placzek EA et al. Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2-arachidonylglycerol. 2008 J. Neurochem. pmid:18778304
Fowler CJ "The tools of the trade"--an overview of the pharmacology of the endocannabinoid system. 2008 Curr. Pharm. Des. pmid:18781976
Ruby MA et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. 2008 Proc. Natl. Acad. Sci. U.S.A. pmid:18794527
DiPatrizio NV and Simansky KJ Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. 2008 J. Neurosci. pmid:18815256
Bajo M et al. Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands. 2009 J. Neurosci. Res. pmid:18816788
Catani MV et al. Expression of the endocannabinoid system in the bi-potential HEL cell line: commitment to the megakaryoblastic lineage by 2-arachidonoylglycerol. 2009 J. Mol. Med. pmid:18820887
Ortar G et al. Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. 2008 J. Med. Chem. pmid:18831576
Kreutz S et al. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. 2009 Glia pmid:18837048
Garcia-Ovejero D et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. 2009 Neurobiol. Dis. pmid:18930143
Lu TS et al. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. 2008 J. Immunol. pmid:18941231
Di Marzo V et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. 2009 Diabetologia pmid:18972095
Hill MN et al. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. 2008 J Neural Transm pmid:18974922
Bisogno T et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. 2009 Biochim. Biophys. Acta pmid:19027877
Long JZ et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. 2009 Nat. Chem. Biol. pmid:19029917
Vignali M et al. The endocannabinoid anandamide inhibits potassium conductance in rat cortical astrocytes. 2009 Glia pmid:19031444
Lehtonen M et al. Mass-spectrometric identification of anandamide and 2-arachidonoylglycerol in nematodes. 2008 Chem. Biodivers. pmid:19035572
Marinelli S et al. The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons. 2008 J. Neurosci. pmid:19074027
Jiang LS et al. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. 2009 Cardiovasc. Res. pmid:19074161
Wang J and Ueda N Biology of endocannabinoid synthesis system. 2009 Prostaglandins Other Lipid Mediat. pmid:19126434
Koppel J et al. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. 2009 Lipids Health Dis pmid:19144193
Schlosburg JE et al. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. 2009 AAPS J pmid:19184452
Maccarrone M et al. Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. 2009 J. Neurochem. pmid:19187444
Bisogno T et al. Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. 2009 ChemMedChem pmid:19266526
Bermúdez-Silva FJ et al. The role of the pancreatic endocannabinoid system in glucose metabolism. 2009 Best Pract. Res. Clin. Endocrinol. Metab. pmid:19285263
Sugiura T Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. 2009 Jan-Feb Biofactors pmid:19319851
Urbanski MJ et al. Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling. 2009 Synapse pmid:19347961
Izzo AA et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. 2009 Br. J. Pharmacol. pmid:19371345
Yates ML and Barker EL Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. 2009 Mol. Pharmacol. pmid:19389920
Hill MN et al. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. 2009 Psychoneuroendocrinology pmid:19394765
Ishii Y et al. F2-isoprostanes and 2-arachidonylglycerol as biomarkers of lipid peroxidation in pigs with hepatic ischemia/reperfusion injury. 2010 J. Surg. Res. pmid:19439322
Nyilas R et al. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. 2009 Eur. J. Neurosci. pmid:19453631
Straiker A and Mackie K Cannabinoid signaling in inhibitory autaptic hippocampal neurons. 2009 Neuroscience pmid:19501632
Kinsey SG et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. 2009 J. Pharmacol. Exp. Ther. pmid:19502530
Greco R et al. Alterations of the endocannabinoid system in an animal model of migraine: evaluation in cerebral areas of rat. 2010 Cephalalgia pmid:19515121
Dowie MJ et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. 2009 Neuroscience pmid:19524019
Maeda N et al. Increased serum anandamide level at ruptured plaque site in patients with acute myocardial infarction. 2009 Fundam Clin Pharmacol pmid:19527302
Grimaldi P et al. The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. 2009 Proc. Natl. Acad. Sci. U.S.A. pmid:19541620
Bowman AL and Makriyannis A Refined homology model of monoacylglycerol lipase: toward a selective inhibitor. 2009 J. Comput. Aided Mol. Des. pmid:19543978
Batetta B et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. 2009 J. Nutr. pmid:19549757
Guasti L et al. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. 2009 Mol Pain pmid:19570201
Wakley AA and Rasmussen EB Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. 2009 Pharmacol. Biochem. Behav. pmid:19602424